SRR5088897
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.700
- XENOBIOTIC_METABOLISM+0.600
- COAGULATION+0.500
- FATTY_ACID_METABOLISM+0.500
- ADIPOGENESIS+0.400
- ANGIOGENESIS+0.400
- CHOLESTEROL_HOMEOSTASIS+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- MYOGENESIS+0.400
- PEROXISOME+0.400
Top 10 suppressed
- E2F_TARGETS-0.700
- MYC_TARGETS_V1-0.700
- G2M_CHECKPOINT-0.600
- MYC_TARGETS_V2-0.600
- DNA_REPAIR-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.400
- MITOTIC_SPINDLE-0.300
- PI3K_AKT_MTOR_SIGNALING-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- MTORC1_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088896 | — | — | 0.949 |
| 2 | 830ff04e-ebca-42d8-a018-0a49315640b5 | — | — | 0.926 |
| 3 | AUR-AFE9-TTM4-A-1-1-R-A742-41 | — | C | 0.894 |
| 4 | SNU761_LIVER | HCC | — | 0.878 |
| 5 | BS_2ADZNNV4 | pilocytic astrocytoma | — | 0.878 |
| 6 | MDT-AP-1254 | Med | Medulloblastoma | 0.877 |
| 7 | TCGA-38-4626-01A-01R-1206-07 | — | cohortMD2 | 0.876 |
| 8 | SRR975594 | — | — | 0.864 |
| 9 | TCGA-05-4403-01A-01R-1206-07 | — | cohortA1 | 0.858 |
| 10 | SRR11296843 | — | — | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.700 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.600 | Inavolisib | — uncovered |
| COAGULATION | 0.500 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.500 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MYOGENESIS | 0.400 | Inavolisib | — uncovered |
| PEROXISOME | 0.400 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |